Ashton Thomas Private Wealth LLC Trims Stock Holdings in Bristol Myers Squibb Company $BMY

Key Points

• Ashton Thomas Private Wealth LLC trimmed its stake in Bristol Myers Squibb (BMY) by 18.2% in Q4, selling 29,169 shares and ending the period with 130,991 shares worth about $7.07 million.
• EVP David V. Elkins sold 30,000 BMY shares at an average of $61.67 (≈$1.85M), cutting his position by 15.85% to 159,248 shares; insiders now own roughly 0.05% of the stock.
• Analysts are mixed with a consensus Hold and a $61.31 average target (ranging from Morgan Stanley’s $40 to Barclays/Piper Sandler’s $75), while BMY missed Q4 EPS ($1.26 vs. $1.65), guided FY2026 EPS to 6.05–6.35, and announced a quarterly dividend of $0.63 (yield ~4.3%).

Ashton Thomas Private Wealth LLC lowered its holdings in shares of Bristol Myers Squibb Company (NYSE:BMY - Free Report) by 18.2% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 130,991 shares of the biopharmaceutical company's stock after selling 29,169 shares during the quarter. Ashton Thomas Private Wealth LLC's holdings in Bristol Myers Squibb were worth $7,066,000 at the end of the most recent reporting period.

Other institutional investors have also recently made changes to their positions in the company. Physician Wealth Advisors Inc. grew its position in shares of Bristol Myers Squibb by 73.5% during the fourth quarter. Physician Wealth Advisors Inc. now owns 477 shares of the biopharmaceutical company's stock worth $26,000 after purchasing an additional 202 shares in the last quarter. Darwin Wealth Management LLC purchased a new stake in shares of Bristol Myers Squibb during the second quarter worth about $25,000. Harbor Capital Advisors Inc. grew its position in shares of Bristol Myers Squibb by 107.2% during the third quarter. Harbor Capital Advisors Inc. now owns 605 shares of the biopharmaceutical company's stock worth $27,000 after purchasing an additional 313 shares in the last quarter. Beacon Financial Strategies CORP purchased a new stake in shares of Bristol Myers Squibb during the fourth quarter worth about $38,000. Finally, KERR FINANCIAL PLANNING Corp purchased a new stake in shares of Bristol Myers Squibb during the third quarter worth about $35,000. Hedge funds and other institutional investors own 76.41% of the company's stock.

Analyst Upgrades and Downgrades

Several analysts recently issued reports on BMY shares. Piper Sandler reiterated an "overweight" rating and set a $75.00 target price (up from $66.00) on shares of Bristol Myers Squibb in a research report on Monday, February 23rd. Leerink Partners increased their target price on Bristol Myers Squibb from $54.00 to $60.00 and gave the stock an "outperform" rating in a research report on Tuesday, January 13th. Barclays started coverage on Bristol Myers Squibb in a research report on Thursday, February 19th. They set an "overweight" rating and a $75.00 target price for the company. Weiss Ratings reiterated a "hold (c)" rating on shares of Bristol Myers Squibb in a research report on Monday, March 23rd. Finally, Morgan Stanley reiterated an "underweight" rating and set a $40.00 target price on shares of Bristol Myers Squibb in a research report on Friday, February 6th. Eight equities research analysts have rated the stock with a Buy rating, ten have given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, Bristol Myers Squibb currently has an average rating of "Hold" and a consensus price target of $61.31.

Insider Activity

In other news, EVP David V. Elkins sold 30,000 shares of the firm's stock in a transaction that occurred on Wednesday, April 1st. The stock was sold at an average price of $61.67, for a total value of $1,850,100.00. Following the completion of the sale, the executive vice president directly owned 159,248 shares of the company's stock, valued at $9,820,824.16. This trade represents a 15.85% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 0.05% of the stock is owned by insiders.

Key Headlines Impacting Bristol Myers Squibb

Here are the key news stories impacting Bristol Myers Squibb this week:

• Positive Sentiment: BMY is being cited as a top defensive, low-volatility, high-yield holding for conservative portfolios, which supports demand from income-focused investors. Bristol-Myers Squibb Company (BMY): Favorite for Conservative Portfolios
• Positive Sentiment: Barclays reiterated a Buy on BMY, a near-term catalyst that can support the stock if positive analysts’ notes draw fresh buying interest. Bristol-Myers Squibb (BMY) Receives a Buy from Barclays
• Neutral Sentiment: Atrium Therapeutics announced it earned a $15M milestone from BMY under a cardiovascular collaboration — confirms ongoing R&D spend and pipeline partnering but is not material for BMY’s top-line. Atrium Therapeutics Earns $15 Million Milestone Payment
• Neutral Sentiment: Bernstein maintains a Hold on BMY — a reminder of mixed analyst views that can keep trading range-bound ahead of results. Bernstein Remains a Hold on Bristol-Myers Squibb (BMY)
• Negative Sentiment: Analysts and previews expect an earnings decline and flag that legacy drug declines and generic/competitive pressure could weigh on revenue — a key reason investors are cautious into Q1. Analysts Estimate Bristol Myers Squibb (BMY) to Report a Decline in Earnings
• Negative Sentiment: Seeking Alpha downgraded BMY from “Buy,” citing muted growth prospects despite a strong pipeline — sentiment that can pressure the stock if echoed by other shops. Bristol Myers Squibb: Strong Pipeline, Weak Outlook (Rating Downgrade)
• Negative Sentiment: BMY and Pfizer will make Eliquis available via Mark Cuban’s Cost Plus platform at a sharply lower transparent price — increases pricing scrutiny and could be viewed as a headwind for high-margin sales of a blockbuster drug. Bristol Myers, Pfizer Bring Eliquis to Cost Plus at $345 Monthly Business Wire: Eliquis via Mark Cuban Cost Plus

Bristol Myers Squibb Stock Performance

NYSE BMY opened at $58.77 on Monday. The stock has a market capitalization of $119.99 billion, a PE ratio of 17.03, a P/E/G ratio of 0.17 and a beta of 0.27. The business has a 50 day simple moving average of $59.69 and a two-hundred day simple moving average of $54.22. The company has a debt-to-equity ratio of 2.32, a current ratio of 1.26 and a quick ratio of 1.14. Bristol Myers Squibb Company has a 1-year low of $42.52 and a 1-year high of $62.89.

Bristol Myers Squibb (NYSE:BMY - Get Free Report) last released its quarterly earnings results on Thursday, February 5th. The biopharmaceutical company reported $1.26 earnings per share for the quarter, missing the consensus estimate of $1.65 by ($0.39). The firm had revenue of $12.50 billion for the quarter, compared to analysts' expectations of $12.24 billion. Bristol Myers Squibb had a net margin of 14.64% and a return on equity of 69.65%. The business's quarterly revenue was up 1.3% compared to the same quarter last year. During the same quarter in the prior year, the business earned $1.67 EPS. Bristol Myers Squibb has set its FY 2026 guidance at 6.050-6.350 EPS. On average, research analysts predict that Bristol Myers Squibb Company will post 6.28 EPS for the current fiscal year.

Bristol Myers Squibb Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, May 1st. Stockholders of record on Thursday, April 2nd will be paid a $0.63 dividend. This represents a $2.52 annualized dividend and a dividend yield of 4.3%. The ex-dividend date of this dividend is Thursday, April 2nd. Bristol Myers Squibb's dividend payout ratio (DPR) is presently 73.04%.

About Bristol Myers Squibb

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company's core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS's marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.

Want to see what other hedge funds are holding BMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol Myers Squibb Company (NYSE:BMY - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.